Heart
01 Jan 2013
A Study of Safety, Tolerability & Efficacy of Certican in de novo Heart Transplant (Tx) Patients
The study is designed to evaluate whether Neoral dose optimization together with a therapeutic drug monitoring of Certican will prevent renal dysfunction as observed in the pivotal cardiac trial while maintaining the efficacy. This objective will be assessed by comparing renal function post-transplant between 2 groups of patients. Official Title…
Blood
01 Jan 2013
SR34006 Compared to Placebo in Patients who have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur. Anticoagulant (blood-thinning) drugs are normally given immediately after the clot is discovered and are continued for a period of 3 or…
Heart
01 Jan 2013
Comparison of sulfonamide COX-2 inhibitors and NSAIDs for cardiovascular risk
Clinical investigations have demonstrated a link between use of the sulfone cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, and increased risk for atherothrombotic events. This increased risk was not observed for a sulfonamide COX-2 inhibitor (celecoxib), indicating a potential non-enzymatic mechanism for rofexocib. To test this hypothesis, researchers compared the independent effects…
Heart
01 Jan 2013
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs
Clinical investigations have demonstrated a link between use of the sulfone cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, and increased risk for atherothrombotic events. This increased risk was not observed for a sulfonamide COX-2 inhibitor (celecoxib), indicating a potential non-enzymatic mechanism for rofexocib. To test this hypothesis, researchers compared the independent effects…
Heart
01 Jan 2013
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)
To evaluate the effectiveness of aldosterone antagonist therapy in reducing all cause mortality in patients who have heart failure with preserved systolic function. Official Title Conditions – Cardiovascular Diseases- Heart Diseases- Heart Failure Study Type Interventional Study Design Treatment, Randomized, Double-Blind, Placebo Control Further Details BACKGROUND: Heart failure (HF)…
Heart
01 Jan 2013
PCI plus intensive medical therapy will be superior to intensive medical therapy alone in reducing all cause mortality or nonfatal MI
PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI. Official Title Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Conditions – Myocardial Ischemia Study Type Interventional Study Design Randomized, Open Label, Uncontrolled, Single…
Heart
01 Jan 2013
Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve)
The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied. Official Title Conditions Congestive Heart Failure Study Type Interventional Study…
Heart
01 Jan 2013
Pexelizumab in Conjunction with Angioplasty in Acute Myocardial Infarction (APEX-AMI)
In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body’s own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 90 days. Official Title…
Heart
01 Jan 2013
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure. Official Title Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure. Conditions Heart Failure, Congestive Study Type…
